Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 5/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.38 |
| ▸ | GRM8 | O00222 | 4/20 | 0.38 |
| ▸ | GRM6 | O15303 | 3/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31440740 | 1.00 | ARG1 (0.57) | ARG1ARG2GRM2GRM5GRM1 | |
| SCHEMBL27198621 | 1.00 | ARG1 (0.57) | ARG1ARG2GRM2GRM5GRM1 | |
| SCHEMBL27198574 | 1.00 | ARG1 (0.57) | ARG1ARG2GRM2GRM5GRM1 | |
| Bromide SCHEMBL27198716 | 0.98 | ARG1 (0.55) | ARG1ARG2GRM2GRM5GRM1 | |
| Bromide SCHEMBL27198559 | 0.98 | ARG1 (0.55) | ARG1ARG2GRM2GRM5GRM1 | |
| Hydrochloric Acid SCHEMBL1806885 | 0.98 | ARG1 (0.55) | ARG1ARG2GRM2GRM5GRM1 | |
| Bromide SCHEMBL27198603 | 0.98 | ARG1 (0.55) | ARG1ARG2GRM2GRM5GRM1 | |
| SCHEMBL10532989 | 0.94 | ARG1 (0.51) | ARG1ARG2GRM2GRM5GRM1 | |
| SCHEMBL2906586 | 0.94 | ARG1 (0.51) | ARG1ARG2GRM2GRM5GRM1 | |
| SCHEMBL1515659 | 0.88 | GRM8 (0.44) | ARG1ARG2GRM2GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590675-B1 | HETEROCYCLIC SIK INHIBITORS | PFIZER (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4590675-A1 | HETEROCYCLIC SIK INHIBITORS | Pfizer Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-119948025-A | Heterocyclic SIK inhibitors | 辉瑞大药厂 | 2025-05-06 | — | — | CN | disclosed |
| US-20240124450-A1 | Novel SIK Inhibitors | PFIZER INC. (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024062360-A1 | HETEROCYCLIC SIK INHIBITORS | PFIZER INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-8269046-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1631633-B1 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEM (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100064933-A1 | Cyclic Bisamides Useful in Formulating Inks for Phase-Change Printing | ARIZONA CHEMICAL COMPANY LLC | 2010-03-18 | — | — | US | disclosed |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1631633-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | Arizona Chemical Company (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960248-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2004106442-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEMICAL COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040231555-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2004-11-25 | — | — | US | disclosed |
| EP-0249434-B1 | Peptide derivatives and processes for their preparation | VYZK USTAV FARM BIOCHEM SP (CZ) | 1994-05-04 | — | — | EP | disclosed |
| US-4898930-A | Peptide derivatives and processes for their preparation | SPOFA, SPOJENE PODNIKY PRO (CS) | 1990-02-06 | — | — | US | disclosed |
| EP-0249434-A2 | Peptide derivatives and processes for their preparation | Vyzkumny ustav pro farmacii a biochemii (CZ) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124450-A1 | Novel SIK Inhibitors | SIK3, SIK2, SIK1 | ARG1 1737/4885ARG2 4022/4885GRM2 2342/4885 |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | FHIT, DDC, MNAT1 | ARG1 1045/4885ARG2 889/4885GRM2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.